About Xeltis
Xeltis is a company based in Zurich (Switzerland) founded in 2006. Xeltis has raised $199.38 million across 14 funding rounds from investors including EQT, European Investment Bank and Kurma Partners. Xeltis offers products and services including Artificial Vessels, Heart Valves, and RestoreX Platform. Xeltis operates in a competitive market with competitors including PECA Labs, Occlutech, Endonovo Therapeutics, Coherex and CoAptus Medical, among others.
- Headquarter Zurich, Switzerland
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$199.38 M (USD)
in 14 rounds
-
Latest Funding Round
$23.34 M (USD), Series E
Jul 28, 2026
-
Investors
EQT
& 14 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Xeltis
Xeltis offers a comprehensive portfolio of products and services, including Artificial Vessels, Heart Valves, and RestoreX Platform.
Devices that regenerate into patients' tissue to treat vascular conditions.
Implants for pulmonary replacement to reduce surgical complications.
ETR-based system for developing self-healing vascular solutions.
People of Xeltis
Unlock access to complete
Unlock access to complete
Funding Insights of Xeltis
Xeltis has successfully raised a total of $199.38M across 14 strategic funding rounds. The most recent funding activity was a Series E round of $23.34 million completed in July 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Xeltis
Xeltis has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include EQT, European Investment Bank and Kurma Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
Venture capital firm investing in healthcare sectors
|
Locked | Locked | Locked | |
|
EQT is recognized as a global investment organization focused on value creation.
|
Locked | Locked | Locked |
Investor details for Xeltis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Xeltis
Investment portfolio details for Xeltis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Xeltis
Detailed financials for Xeltis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Xeltis Comparisons
Peer comparison for Xeltis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Xeltis
Xeltis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PECA Labs, Occlutech, Endonovo Therapeutics, Coherex and CoAptus Medical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pediatric cardiac surgical devices are developed for congenital heart defects.
|
|
| Locked | Locked | Locked |
Provider of minimally invasive cardiac devices for congenital heart defects, stroke prevention and heart failure
|
|
| Locked | Locked | Locked |
Bioelectronic devices are developed for regenerative medicine therapies.
|
|
| Locked | Locked | Locked |
Structural heart disease conditions are addressed with implant devices.
|
|
| Locked | Locked | Locked |
Develops non-implant therapeutics for treating patent foramen ovale, a structural heart defect.
|
Detailed competitors of Xeltis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Xeltis
Complete news archive for Xeltis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Xeltis
Xeltis was founded in 2006 and raised its 1st funding round 8 years after it was founded.
Xeltis is headquartered in Zurich, Switzerland.
Xeltis is a funded company, having raised a total of $199.38M across 14 funding rounds to date.
Xeltis was founded in 2006 in Zurich, Switzerland, where bioabsorbable synthetic heart valves and vascular grafts are developed for cardiovascular applications. These implants are designed to mimic natural valves and vessels, enabling the body to heal by forming native tissue as the synthetic matrix is gradually absorbed. Operations center on pediatric solutions, including a flagship pulmonary valve replacement for congenital heart malformations. The sector involves regenerative medical devices.
Xeltis's top competitors include PECA Labs, Endonovo Therapeutics and Occlutech.
Xeltis offers Artificial Vessels, Heart Valves, and RestoreX Platform.
Xeltis has 15 investors. Key investors include EQT, European Investment Bank, Kurma Partners, European Union, and Life Sciences Partners.